Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression (Q37179585)

18 August 2017

1 reference

title

Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression (English)

1 reference

18 August 2017

main subject

prostatic hypertrophy

1 reference

Jonathan M Levitt

1

1 reference

18 August 2017

Kevin M Slawin

series ordinal

2

1 reference

18 August 2017

publication date

1 July 2007

1 reference

18 August 2017

published in

Current urology reports

1 reference

18 August 2017

volume

8

1 reference

18 August 2017

issue

4

1 reference

18 August 2017

page(s)

269-274

1 reference

Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer

18 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11934-007-0072-Y

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

21 January 2018

1 reference

12 December 2020

Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step.

1 reference

12 December 2020

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

12 December 2020

Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening

1 reference

12 December 2020

Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.

1 reference

12 December 2020

Biology of prostate-specific antigen

1 reference

12 December 2020

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study

1 reference

12 December 2020

The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.

1 reference

12 December 2020

Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

1 reference

12 December 2020

Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable?

1 reference

12 December 2020

Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.

1 reference

12 December 2020

A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer

1 reference

12 December 2020

Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer

1 reference

12 December 2020

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

1 reference

12 December 2020

Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease

1 reference

12 December 2020

Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging

1 reference

12 December 2020

A structural model for the prostate disease marker, human prostate-specific antigen

1 reference

12 December 2020

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

12 December 2020

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

12 December 2020

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

1 reference

12 December 2020

Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia

1 reference

12 December 2020

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

1 reference

12 December 2020

Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia

1 reference

12 December 2020

Purification of a human prostate specific antigen

1 reference

12 December 2020

Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry

1 reference

12 December 2020

Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men.

1 reference

12 December 2020

A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum

1 reference

12 December 2020

Molecular cloning of human prostate specific antigen cDNA.

1 reference

12 December 2020

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer

1 reference

12 December 2020

Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

Prostate specific antigen--new applications in breast and other cancers

1 reference

12 December 2020

A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.

1 reference

12 December 2020

The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer

1 reference

12 December 2020

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

1 reference

12 December 2020

Benign prostatic hyperplasia: a progressive disease of aging men.

1 reference

12 December 2020

Human tissue kallikreins: physiologic roles and applications in cancer.

1 reference

12 December 2020

Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.

1 reference

12 December 2020

Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer

1 reference

12 December 2020

Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2

1 reference

12 December 2020

Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer

1 reference

12 December 2020

Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen

1 reference

12 December 2020

Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I

1 reference

12 December 2020

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

1 reference

12 December 2020

10.1007/S11934-007-0072-Y

Identifiers

DOI

1 reference

18 August 2017

1 reference